|
|
|
|
Vol. 29, Issue 8, 1146-1155, August 2001
Department of Pharmacokinetics and Drug Metabolism, Purdue Pharma
L.P., Ardsley, New York (V.S., A.P.T.); and TNO BIBRA International
Ltd., Carshalton, Surrey, United Kingdom (A.B.R., D.G.W., P.J.Y.,
R.J.P., B.G.L.)
The metabolism of cis-tramadol has been studied in
human liver microsomes and in cDNA-expressed human cytochrome P-450
(CYP) isoforms. Human liver microsomes catalyzed the NADPH-dependent metabolism of tramadol to the two primary tramadol metabolites, namely,
O-desmethyl-tramadol (metabolite M1) and
N-desmethyl-tramadol (metabolite M2). In addition,
tramadol was also metabolized to two minor secondary metabolites (each
comprising
3.0% of total tramadol metabolism), namely,
N,N-didesmethyl-tramadol (metabolite M3)
and N,O-didesmethyl-tramadol (metabolite
M5). Kinetic analysis revealed that multiple CYP enzymes were involved
in the metabolism of tramadol to both M1 and M2. For the high-affinity
enzymes involved in M1 and M2 formation, Km
values were 116 and 1021 µM, respectively. Subsequent reaction
phenotyping studies were performed with a tramadol substrate
concentration of 250 µM. In studies with characterized human liver
microsomal preparations, good correlations were observed between
tramadol metabolism to M1 and M2 and enzymatic markers of CYP2D6 and
CYP2B6, respectively. Tramadol was metabolized to M1 by cDNA-expressed
CYP2D6 and to M2 by CYP2B6 and CYP3A4. Tramadol metabolism in human
liver microsomes to M1 and M2 was markedly inhibited by the CYP2D6
inhibitor quinidine and the CYP3A4 inhibitor troleandomycin,
respectively. In summary, this study demonstrates that
cis-tramadol can be metabolized to tramadol metabolites
M1, M2, M3, and M5 in human liver microsomal preparations. By kinetic analysis and the results of the reaction phenotyping studies, tramadol
metabolism in human liver is catalyzed by multiple CYP isoforms.
Hepatic CYP2D6 appears to be primarily responsible for M1 formation,
whereas M2 formation is catalyzed by CYP2B6 and CYP3A4.
This article has been cited by other articles:
![]() |
H. Shen, M. M. He, H. Liu, S. A. Wrighton, L. Wang, B. Guo, and C. Li Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17 Drug Metab. Dispos., August 1, 2007; 35(8): 1292 - 1300. [Abstract] [Full Text] [PDF] |
||||